Spectral awaits broader cardiac patent:
This article was originally published in Clinica
The US Patent Office says it will issue a new, broader cardiac panel testing patent to Spectral Diagnostics. Spectral's original 1994 patent covered panel tests using myoglobin, myosin light-chains and either CK-MB, troponin-I or troponin-T, in chest pain patients. The new patent will extend the range of analyte combinations and be independent of test format. New analytes include glycogen phosphorylase, fatty acid binding proteins and carbonic anhydrase, among others.
You may also be interested in...
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”